Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Jun 2

PMID 34064473

Citations 21

Authors

Nina Oparina

Malin C Erlandsson

Anna Faldt Beding

Toshima Parris

Khalil Helou

Per Karlsson

Zakaria Einbeigi

Maria I Bokarewa

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) histological and molecular classifications significantly improved the treatment strategy and prognosis. Inhibitor of apoptosis BIRC5/survivin is often overexpressed in cancers, however, indications of its importance in BC are inconsistent. We integrate BIRC5 protein and mRNA measures with clinical associates and long-term outcome in three independent cohorts Protein levels of BIRC5 were measured in primary lysates of 845 patients of the West Swedish BC cohort (VGR-BC) and linked to 5- and 27-years survival. The results were externally validated in transcriptomic data from METABRIC and SCAN-B cohorts. Survival analysis showed that high levels of BIRC5 were consistently associated with a poor probability of 5-year overall survival. High BIRC5 in VGR-BC contributed negatively to the disease-specific survival at 5 and 27 years. Subsets with different status by ER (estrogen receptor) expression and presence of nodal metastasis supported independent association of high BIRC5 with poor prognosis in all cohorts. In METABRIC and SCAN-B cohorts, high levels of BIRC5 mRNA were associated with the basal-like and luminal B molecular BC subtypes and with increasing histologic grade. BIRC5 is a sensitive survival marker that acts independent of ER and nodal status, and its levels need to be considered when making treatment decisions.

Citing Articles

Bioinformatics-Driven Investigations of Signature Biomarkers for Triple-Negative Breast Cancer.

Handa S, Puri S, Chatterjee M, Puri V Bioinform Biol Insights. 2025; 19:11779322241271565.

PMID: 40034579 PMC: 11873876. DOI: 10.1177/11779322241271565.

Esophageal chemical burns as a risk factor for esophageal malignancies: in-silico analyses - experimental research.

Khosravani H, Disfani R, Farhadi B, Tohidian M, Garrosi L, Shirvani P Ann Med Surg (Lond). 2024; 86(9):5170-5178.

PMID: 39239040 PMC: 11374246. DOI: 10.1097/MS9.0000000000002317.

Novel strategy for activating gene expression through triplex DNA formation targeting epigenetically suppressed genes.

Notomi R, Sasaki S, Taniguchi Y RSC Chem Biol. 2024; 5(9):884-890.

PMID: 39211471 PMC: 11353075. DOI: 10.1039/d4cb00134f.

Survivin as a Therapeutic Target for the Treatment of Human Cancer.

Wang Q, Greene M Cancers (Basel). 2024; 16(9).

PMID: 38730657 PMC: 11083197. DOI: 10.3390/cancers16091705.

BIRC5 expression by race, age and clinical factors in breast cancer patients.

Hamilton A, Walens A, Van Alsten S, Olsson L, Nsonwu-Farley J, Gao X Breast Cancer Res. 2024; 26(1):50.

PMID: 38515208 PMC: 10956264. DOI: 10.1186/s13058-024-01792-y.

References

McKenzie J, Liu T, Jung J, Jones B, Ekiz H, Welm A . Survivin promotion of melanoma metastasis requires upregulation of α5 integrin. Carcinogenesis. 2013; 34(9):2137-44. PMC: 3765044. DOI: 10.1093/carcin/bgt155. View

Nordenskjold A, Fohlin H, Albertsson P, Arnesson L, Chamalidou C, Einbeigi Z . No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study. Ann Oncol. 2015; 26(6):1149-1154. DOI: 10.1093/annonc/mdv159. View

Kos Z, Roblin E, Kim R, Michiels S, Gallas B, Chen W . Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. NPJ Breast Cancer. 2020; 6:17. PMC: 7217863. DOI: 10.1038/s41523-020-0156-0. View

. Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment. Ont Health Technol Assess Ser. 2020; 20(10):1-234. PMC: 7143374. View

Crawford D, Cowan S, Hyder S, McMenamin M, Smith D, Leake R . New storage procedure for human tumor biopsies prior to estrogen receptor measurement. Cancer Res. 1984; 44(6):2348-51. View

Grossman D, Kim P, Schechner J, Altieri D . Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A. 2001; 98(2):635-40. PMC: 14640. DOI: 10.1073/pnas.98.2.635. View

Fitzgibbons P, Connolly J, Page D . Updated protocol for the examination of specimens from patients with carcinomas of the breast. Cancer Committee. Arch Pathol Lab Med. 2000; 124(7):1026-33. DOI: 10.5858/2000-124-1026-UPFTEO. View

Ciesielski M, Ahluwalia M, Munich S, Orton M, Barone T, Chanan-Khan A . Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother. 2010; 59(8):1211-21. PMC: 4603658. DOI: 10.1007/s00262-010-0845-x. View

Curtis C, Shah S, Chin S, Turashvili G, Rueda O, Dunning M . The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012; 486(7403):346-52. PMC: 3440846. DOI: 10.1038/nature10983. View

10.

Song J, Su H, Zhou Y, Guo L . Prognostic value of survivin expression in breast cancer patients: a meta-analysis. Tumour Biol. 2013; 34(4):2053-62. DOI: 10.1007/s13277-013-0848-2. View

11.

Haibe-Kains B, Desmedt C, Loi S, Culhane A, Bontempi G, Quackenbush J . A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst. 2012; 104(4):311-25. PMC: 3283537. DOI: 10.1093/jnci/djr545. View

12.

Ahmed W, Malik M, Saeed M, Haq F . Copy number profiling of Oncotype DX genes reveals association with survival of breast cancer patients. Mol Biol Rep. 2018; 45(6):2185-2192. DOI: 10.1007/s11033-018-4379-1. View

13.

Jezequel P, Campone M, Gouraud W, Guerin-Charbonnel C, Leux C, Ricolleau G . bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat. 2011; 131(3):765-75. DOI: 10.1007/s10549-011-1457-7. View

14.

Li Y, Ma X, Wu X, Liu X, Liu L . Prognostic significance of survivin in breast cancer: meta-analysis. Breast J. 2014; 20(5):514-24. DOI: 10.1111/tbj.12303. View

15.

Nuncia-Cantarero M, Martinez-Canales S, Andres-Pretel F, Santpere G, Ocana A, Galan-Moya E . Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer. Breast Cancer Res Treat. 2018; 168(3):613-623. PMC: 5842257. DOI: 10.1007/s10549-017-4652-3. View

16.

Fragomeni S, Sciallis A, Jeruss J . Molecular Subtypes and Local-Regional Control of Breast Cancer. Surg Oncol Clin N Am. 2017; 27(1):95-120. PMC: 5715810. DOI: 10.1016/j.soc.2017.08.005. View

17.

Dedic Plavetic N, Jakic-Razumovic J, Kulic A, Vrbanec D . Prognostic value of proliferation markers expression in breast cancer. Med Oncol. 2013; 30(2):523. DOI: 10.1007/s12032-013-0523-x. View

18.

Hamy A, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretiere J . BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy. Breast Cancer Res Treat. 2016; 159(3):499-511. DOI: 10.1007/s10549-016-3961-2. View

19.

Khan S, Ferguson Bennit H, Turay D, Perez M, Mirshahidi S, Yuan Y . Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer. 2014; 14:176. PMC: 3995700. DOI: 10.1186/1471-2407-14-176. View

20.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View